Cubist Systematic Strategies LLC Takes $56,000 Position in Genelux Co. (NASDAQ:GNLX)

Cubist Systematic Strategies LLC bought a new stake in Genelux Co. (NASDAQ:GNLX) in the second quarter, according to the company in its most recent 13F filing with the Securities and Exchange Commission. The firm bought 28,663 shares of the company’s stock, valued at approximately $56,000. Cubist Systematic Strategies LLC owned 0.08% of Genelux as of its most recent SEC filing.

A number of other institutional investors and hedge funds also recently made changes to their positions in GNLX. Woodward Diversified Capital LLC lifted its stake in shares of Genelux by 0.3% in the 1st quarter. Woodward Diversified Capital LLC now owns 1,085,957 shares of the company’s stock valued at $6,983,000 after purchasing an additional 3,687 shares during the period. SageView Advisory Group LLC purchased a new position in Genelux during the first quarter valued at $121,000. Vanguard Group Inc. raised its stake in Genelux by 2.4% during the first quarter. Vanguard Group Inc. now owns 1,023,030 shares of the company’s stock valued at $6,578,000 after buying an additional 24,220 shares during the last quarter. LifeSteps Financial Inc. raised its stake in Genelux by 50.2% during the second quarter. LifeSteps Financial Inc. now owns 66,536 shares of the company’s stock valued at $130,000 after buying an additional 22,227 shares during the last quarter. Finally, Miracle Mile Advisors LLC purchased a new position in Genelux during the second quarter valued at $58,000. Hedge funds and other institutional investors own 37.33% of the company’s stock.

Genelux Price Performance

GNLX stock opened at $3.09 on Thursday. Genelux Co. has a 1-year low of $1.60 and a 1-year high of $20.62. The business has a fifty day moving average price of $2.34 and a 200-day moving average price of $2.76. The stock has a market capitalization of $106.15 million, a P/E ratio of -3.19 and a beta of -1.54.

Genelux (NASDAQ:GNLX) last posted its quarterly earnings results on Wednesday, August 14th. The company reported ($0.22) earnings per share for the quarter, missing the consensus estimate of ($0.19) by ($0.03). As a group, analysts anticipate that Genelux Co. will post -0.9 earnings per share for the current year.

Insider Transactions at Genelux

In other news, major shareholder Aladar Szalay sold 33,080 shares of the business’s stock in a transaction on Friday, September 13th. The stock was sold at an average price of $2.57, for a total value of $85,015.60. Following the completion of the transaction, the insider now owns 599,821 shares in the company, valued at $1,541,539.97. The trade was a 0.00 % decrease in their ownership of the stock. The transaction was disclosed in a document filed with the Securities & Exchange Commission, which is available through this link. Insiders sold 331,062 shares of company stock worth $736,831 over the last quarter. 9.30% of the stock is currently owned by insiders.

Analysts Set New Price Targets

A number of research analysts have issued reports on GNLX shares. Roth Capital upgraded Genelux to a “strong-buy” rating in a research note on Tuesday, August 27th. HC Wainwright reiterated a “buy” rating and set a $32.00 price objective on shares of Genelux in a research note on Thursday, August 15th. Finally, Roth Mkm started coverage on Genelux in a research note on Tuesday, August 27th. They set a “buy” rating and a $10.00 price objective for the company. Four analysts have rated the stock with a buy rating and one has issued a strong buy rating to the stock. Based on data from MarketBeat, Genelux has an average rating of “Buy” and a consensus price target of $22.33.

About Genelux

Genelux Corporation, a clinical-stage biopharmaceutical company, focuses on developing next-generation oncolytic viral immunotherapies for patients suffering from aggressive and/or difficult-to-treat solid tumor types. Its lead product candidate is Olvi-Vec, a proprietary modified strain of the vaccinia virus for the treatment of ovarian cancer and non-small cell lung cancer.